Human Vaccines Market to Reach $19.2 Billion by 2010, According to New Report by Global Industry Analysts, Inc.

Driven by technology and globalization moves, the global human vaccines market is forecast to reach US$19.2 billion by 2010. Key growth propellers for the vaccines market include the development of new therapeutic and prophylactic vaccines for combating HIV, SARS, and cancer, apart from other fatal diseases

San Jose, California, July 12, 2007 -- Though prophylactic vaccines remain the biggest earners in the human vaccines market, therapeutic vaccines in the pipeline could spring major surprises in the years ahead. Global Prophylactic vaccines market is estimated at US$11.6 billion for 2007. Although accounting for a meager share, Therapeutic vaccines market is expected to record the fastest growth garnering sales worth US$3.3 billion by 2010.

United States represents the largest market for human vaccines with sales estimated at US$6.9 billion for 2007. Within Europe, France, Germany, and United Kingdom together account for more than 3/4th of the market. In Japan, Pediatric prophylactic vaccines sales are likely to grow at a compounded annual rate of 9.9% over the period 2005-2010. Human vaccines market in Asia-Pacific is projected to reach US$1.3 billion by the year 2010.

Most multinational companies engaged in vaccine production are based in the US and Europe.

These regions have gained prominence on the landscape, as large companies line up premium range therapeutic vaccines to be launched once regulatory clearances are obtained. Pediatric combination vaccines, another new entrant in the vaccines market are forecast to fuel growth in the coming years. The market is expected to witness new levels with adoption of novel vaccine delivery mechanisms such as edible, oral, and mucosal. Also critical to market success is the need for using improved adjuvants in vaccines for optimal immunogenicity.

Therapeutic vaccines are currently in various stages of development and are forecast to grow rapidly once introduced into the market. Companies, both established and upcoming are sinking a major chunk of research resources into the development of therapeutic vaccines capable of fighting diseases such as cancer, AIDS, and other diseases. Combination therapeutics is gaining increasing importance and is expected to witness several joint ventures. The market is expected to witness more than 18 new products for cancer treatment, AIDS, neurological diseases, autoimmune diseases, cardiovascular diseases, and nicotine and cocaine addiction in the near future.

Dominant players in the market comprise leading pharmaceutical companies including Sanofi-Aventis, GlaxoSmithKline, Wyeth, and Merck. These companies together command about 80% share of the global human vaccines market. ALK remains the global leader for allergy vaccines. Players developing novel, safe and effective vaccines against the fatal diseases are expected to the have the larger market pie.

The report titled "Human Vaccines: A Global Strategic Business Report" covers major market dynamics, trends, issues, patents, and competition pertaining to the Human Vaccines market on a global as well as regional level. The report enumerates recent developments, mergers, acquisitions and other strategic industry activities. Product segments analyzed in the study include Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines. Analysis is presented for established and emerging markets including United States, Japan, France, Germany, United Kingdom, Italy, Spain, Asia-Pacific, and Latin America.

« Back